Allogeneic hematopoietic SCT in multiple myeloma: Long-term results from a single institution

Bone Marrow Transplantation

Volumn 50, Issue 5, 2015, Pages 658-662

  Rosinol L ^a   Jimenez R ^a   Rovira, M ^a   Martinez C ^a   Fernandez Aviles F ^a   Marin P ^a   Suarez Lledo M ^a   Gutierrez Garcia G ^a   Fernandez De Larrea C ^a   Carreras, E ^a   Urbano Ispizua, A ^a,b   Blade J ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Josep Carreras Leukaemia Research Institute   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOGRAFT; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGED; ALLOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84928929702     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.320     Document Type: Article

References (30)

1. Ludwig H, Bolejack V, Crowley J, Bladé J, San Miguel J, Kyle RA et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28: 1599-05.
2. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
3. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927-1929.
4. Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
5. Bensinger WI, Bucker CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on oucome. Blood 1996; 88: 2787-2793.
6. Gahrton G, Stevenson H, Cavo M, Apperley J, Bacigalupo A, Björkstrand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centre. Br J Haematol 2001; 113: 209-216.
7. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simón JA et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521-4530.
8. Gahrton G, Iacobelli S, Björkstrand B, Hegnbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMTNMAM2000 study. Blood 2013; 121: 5055-5063.
9. Bladé J, Rosinõl L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655-3663.
10. Chng WJ, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269-277.
11. Moreau P, Cavo M, Sonneveld P, Rosinõl L, Attal M, Pezzi A et al. The combination of ISS 3, high LDH and t(4;14) and/or del (17p) identify a simple prognostic index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. J Clin Oncol 2014; 32: 2173-2180.
12. Durie BG, Harousseau JL, San Miguel J, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Peto R, Pike MC. Conservation of the approximation sigma (O-E)2-E in the log-rank test for survival data or tumor incidence data. Biometrics 1971; 29: 579-584.
15. Rosinõl L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593.
16. Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosinõl L et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol 2013; 163: 474-482.
17. Gahrton G. Progress in allogeneic transplantation for multiple myeloma. Eur J Haematol 2010; 85: 279-289.
18. Crawley C, Iacobelly S, BJörkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rated compared with myeloablative conditioning. Blood 2007; 109: 3588-3594.
19. Gahrton G, Iacobelly S, Bandini G, Björkstrand B, Corradini P, Crawley C et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007; 92: 1513-1518.
20. Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MHJ et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728-1733.
21. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383-3391.
22. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F et al. Nonmyeloablative allografing for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375-3382.
23. El-Cheikh J, Crocchhiolo R, Furst S, Stoppa AM, Ladaique P, Faucher C et al. Long-term outcome after allogeneic stem-cell transplantation with reducedintensity conditioning in patients with multiple myeloma. Am J Hematol 2013; 88: 370-374.
24. Bensinger W, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012; 47: 1312-1317.
25. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a g analysis. Blood 2011; 118: 1979-1988.
26. Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012; 47: 749-756.
27. Holtan SG, Pasquini M, Weisdorf DJ. Acute GvHD: a bench to bedside update. Blood 2014; 124: 363-367.
28. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapsefree survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859-1866.
29. Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand Hematology 2012; 2012: 230-236.
30. Kröger N, Einsele H, Derigs G, Wandt H, Krüll A, Zander A. Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. Biol Blood Marrow Transplant 2010; 16: 861-864.